Array And Oncothyreon Team Up On Oral HER2 Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncothyreon agreed to pay $10 million upfront for rights to Array’s oral HER2 inhibitor in development for breast cancer. Under the arrangement, Oncothyreon will fund and conduct proof-of-concept studies, but both companies will be responsible for Phase III development and potentially commercialization.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.